{"id":"triple-therapy-with-ritonavir","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)"},{"rate":"10-20","effect":"Taste perversion"},{"rate":"5-10","effect":"Hepatotoxicity"},{"rate":"15-30","effect":"Lipid abnormalities (elevated triglycerides and cholesterol)"},{"rate":"5-15","effect":"Hyperglycemia"},{"rate":"variable","effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL3182552","moleculeType":"Small molecule","molecularWeight":"720.96"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ritonavir inhibits the HIV-1 protease enzyme, which is essential for processing viral precursor proteins into functional structural and enzymatic proteins. By blocking this protease activity, ritonavir prevents the formation of mature, infectious viral particles. In triple therapy regimens, ritonavir is often used as a pharmacokinetic booster at sub-therapeutic doses to inhibit cytochrome P450 metabolism and increase plasma concentrations of other protease inhibitors.","oneSentence":"Ritonavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:14:43.152Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (as part of antiretroviral combination therapy)"},{"name":"Pharmacokinetic booster for other protease inhibitors in combination antiretroviral regimens"}]},"trialDetails":[{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT06338826","phase":"PHASE2","title":"Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-02-01","conditions":"HIV Infections, HBV Coinfection","enrollment":140},{"nctId":"NCT01511809","phase":"PHASE3","title":"Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2010-09","conditions":"HIV-1 Infection","enrollment":117},{"nctId":"NCT04022967","phase":"PHASE3","title":"ANRS 12372 MODERATO Study","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2020-09-21","conditions":"HIV-1-infection","enrollment":480},{"nctId":"NCT00028366","phase":"NA","title":"Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":56},{"nctId":"NCT04138199","phase":"","title":"A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation","status":"TERMINATED","sponsor":"AbbVie","startDate":"2019-11-01","conditions":"HIV-1 Infection","enrollment":239},{"nctId":"NCT02383108","phase":"PHASE2, PHASE3","title":"Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2016-06","conditions":"HIV Infection","enrollment":318},{"nctId":"NCT03020082","phase":"PHASE3","title":"Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2016-06","conditions":"Chronic Hepatitis C","enrollment":141},{"nctId":"NCT02431975","phase":"PHASE4","title":"Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial","status":"COMPLETED","sponsor":"Columbia University","startDate":"2015-08","conditions":"HIV","enrollment":73},{"nctId":"NCT01792570","phase":"PHASE3","title":"DRV/r + RPV QD: Efficacy and Toxicity Reduction","status":"COMPLETED","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2014-09-30","conditions":"Human Immunodeficiency Virus","enrollment":37},{"nctId":"NCT02581202","phase":"","title":"The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-12-21","conditions":"HIV-1 Infection","enrollment":216},{"nctId":"NCT03020004","phase":"PHASE2","title":"Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2016-01","conditions":"Chronic Hepatitis C","enrollment":70},{"nctId":"NCT01009437","phase":"PHASE1","title":"Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2010-05-26","conditions":"Breast Cancer","enrollment":28},{"nctId":"NCT01448707","phase":"PHASE3","title":"A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2012-03-15","conditions":"Human Immunodeficiency Virus (HIV) Infections, Acquired Immunodeficiency Syndrome (AIDS) Virus","enrollment":274},{"nctId":"NCT00326963","phase":"PHASE4","title":"BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-03","conditions":"HIV Infections","enrollment":142},{"nctId":"NCT02646111","phase":"PHASE3","title":"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors (\"PI\") Failures","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2016-01","conditions":"Hepatitis C","enrollment":120},{"nctId":"NCT00159224","phase":"PHASE4","title":"Induction-maintenance of Lopinavir/r in HIV-infected Subjects","status":"COMPLETED","sponsor":"Fundación Huésped","startDate":"2005-04","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT02249130","phase":"PHASE2","title":"Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-03","conditions":"HIV Infections","enrollment":18},{"nctId":"NCT01471821","phase":"PHASE4","title":"Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2011-10","conditions":"HIV Infection","enrollment":250},{"nctId":"NCT00946595","phase":"PHASE2, PHASE3","title":"Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2009-11","conditions":"HIV Infections","enrollment":420},{"nctId":"NCT00517192","phase":"PHASE3","title":"Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2007-09","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT01391013","phase":"PHASE2","title":"A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Janssen-Cilag S.p.A.","startDate":"2009-06","conditions":"Human Immunodeficiency Virus 1","enrollment":30},{"nctId":"NCT00865007","phase":"PHASE4","title":"Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2008-12","conditions":"HIV Infection, Lipodystrophy, HIV Infections","enrollment":88},{"nctId":"NCT01166477","phase":"PHASE4","title":"Clinical Trial, Open-label, Randomised, in Order to Compare the Quality of Life for Those VIH+ Patients That Start With Monotherapy on LPV/r Tablets Vs. Triple Therapy With a Boosted Protease Inhibitor","status":"COMPLETED","sponsor":"Sociedad Andaluza de Enfermedades Infecciosas","startDate":"2010-01","conditions":"HIV Infection","enrollment":228},{"nctId":"NCT00458302","phase":"PHASE3","title":"Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2007-06","conditions":"HIV Infections, AIDS Virus, Human Immunodeficiency Virus","enrollment":256},{"nctId":"NCT01230580","phase":"PHASE4","title":"Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)","status":"UNKNOWN","sponsor":"Medical Research Council","startDate":"2008-11","conditions":"HIV Infection, Acquired Immunodeficiency Syndrome","enrollment":587},{"nctId":"NCT01013987","phase":"PHASE4","title":"Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients","status":"UNKNOWN","sponsor":"Fundación Huésped","startDate":"2010-02","conditions":"HIV-1 Adults Patients, AIDS, Triple Class Failure","enrollment":60},{"nctId":"NCT00234910","phase":"PHASE3","title":"Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients","status":"COMPLETED","sponsor":"Abbott","startDate":"2005-01","conditions":"HIV Infection","enrollment":152},{"nctId":"NCT00234923","phase":"PHASE3","title":"Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients","status":"COMPLETED","sponsor":"Abbott","startDate":"2003-08","conditions":"HIV Infection","enrollment":138},{"nctId":"NCT00114933","phase":"PHASE4","title":"\"OK 2004 Study\" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects","status":"COMPLETED","sponsor":"Arribas, Jose R., M.D.","startDate":"2005-01","conditions":"HIV Infection","enrollment":200},{"nctId":"NCT00335686","phase":"PHASE4","title":"Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2003-10","conditions":"HIV Infections","enrollment":67}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Triple therapy with ritonavir","genericName":"Triple therapy with ritonavir","companyName":"Sociedad Andaluza de Enfermedades Infecciosas","companyId":"sociedad-andaluza-de-enfermedades-infecciosas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ritonavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and maturation of infectious HIV particles. Used for HIV-1 infection (as part of antiretroviral combination therapy), Pharmacokinetic booster for other protease inhibitors in combination antiretroviral regimens.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}